BONE AND JOINT INFECTION SOCIETY C.I.C.

Company limited by guarantee

Company Registration Number:
14861451 (England and Wales)

Unaudited statutory accounts for the year ended 31 May 2024

Period of accounts

Start date: 11 May 2023

End date: 31 May 2024

BONE AND JOINT INFECTION SOCIETY C.I.C.

Contents of the Financial Statements

for the Period Ended 31 May 2024

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

BONE AND JOINT INFECTION SOCIETY C.I.C.

Directors' report period ended 31 May 2024

The directors present their report with the financial statements of the company for the period ended 31 May 2024

Directors

The directors shown below have held office during the whole of the period from
11 May 2023 to 31 May 2024

D W Shields
Dr N S Premchand
R Morgan-Jones
J Kozdryk
M B Jamal
V Gupta
P-R Forget


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
21 October 2024

And signed on behalf of the board by:
Name: D W Shields
Status: Director

BONE AND JOINT INFECTION SOCIETY C.I.C.

Profit And Loss Account

for the Period Ended 31 May 2024

13 months to 31 May 2024


£
Turnover: 10,450
Gross profit(or loss): 10,450
Administrative expenses: ( 4,096 )
Operating profit(or loss): 6,354
Profit(or loss) before tax: 6,354
Tax: ( 1,207 )
Profit(or loss) for the financial year: 5,147

BONE AND JOINT INFECTION SOCIETY C.I.C.

Balance sheet

As at 31 May 2024

Notes 13 months to 31 May 2024


£
Current assets
Cash at bank and in hand: 9,216
Total current assets: 9,216
Creditors: amounts falling due within one year: 3 ( 3,884 )
Net current assets (liabilities): 5,332
Total assets less current liabilities: 5,332
Accruals and deferred income: ( 185 )
Total net assets (liabilities): 5,147
Members' funds
Profit and loss account: 5,147
Total members' funds: 5,147

The notes form part of these financial statements

BONE AND JOINT INFECTION SOCIETY C.I.C.

Balance sheet statements

For the year ending 31 May 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 21 October 2024
and signed on behalf of the board by:

Name: D W Shields
Status: Director

The notes form part of these financial statements

BONE AND JOINT INFECTION SOCIETY C.I.C.

Notes to the Financial Statements

for the Period Ended 31 May 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

BONE AND JOINT INFECTION SOCIETY C.I.C.

Notes to the Financial Statements

for the Period Ended 31 May 2024

  • 2. Employees

    13 months to 31 May 2024
    Average number of employees during the period 0

BONE AND JOINT INFECTION SOCIETY C.I.C.

Notes to the Financial Statements

for the Period Ended 31 May 2024

3. Creditors: amounts falling due within one year note

13 months to 31 May 2024
£
Taxation and social security 1,207
Other creditors 2,677
Total 3,884

COMMUNITY INTEREST ANNUAL REPORT

BONE AND JOINT INFECTION SOCIETY C.I.C.

Company Number: 14861451 (England and Wales)

Year Ending: 31 May 2024

Company activities and impact

We have run a conference and some webinars to discuss best practice for doctors treating infections in patients with implants. This has ensured that doctors and colleagues will still continue to offer the most contemporary treatment to patients with musculoskeletal infections

Consultation with stakeholders

This years inaugural conference included over 150 of the UKs leading surgeons, nurses and pharmacists. The knowledge exchange and networking was invaluable.

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
21 October 2024

And signed on behalf of the board by:
Name: D W Shields
Status: Director